Company: CERO
Filing Date: 2025-06-16
Form Type: 424B3
Source: 0001213900-25-054769
Chunk: 8

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-06-16
Form: 424B3
Chunk 8
---
 level, that the Hearings Panel will grant the Company’s appeal
of the delisting determination. Accordingly, there can be no assurance that the Company will ultimately regain compliance and remain listed
on the Nasdaq Capital Market.

Cautionary Note Regarding Forward Looking Statements

This
communication contains statements that are forward-looking and as such are not historical facts. This includes, without limitation, statements
regarding the Company’s plans to appeal the Company’s intent or ability to regain compliance with the Bid Price Requirement,
the outcome of a Nasdaq hearing and appeal process, and the anticipated actions by the Nasdaq Staff and the Company’s responses
and their anticipated outcome, and the ability for the Company’s securities to remain listed on Nasdaq. These statements constitute
projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the
fact that they do not relate strictly to historical or current facts. When used in this communication, words such as “anticipate,”
“believe,” “continue,” “could,” “estimate,” “expect,” “intend,”
“may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,”
“should,” “strive,” “would” and similar expressions may identify forward-looking statements, but the
absence of these words does not mean that a statement is not forward-looking. When the Company discusses its strategies or plans, it is
making projections, forecasts or forward-looking statements. Such statements are based on the beliefs of, as well as assumptions made
by and information currently available to, the Company’s management.

Actual
results could differ from those implied by the forward-looking statements in this communication. Certain risks that could cause actual
results to differ include, among others: outcomes of the Company’s planned clinical trials and studies may not be favorable; that
one or more of the Company’s product candidate programs will not proceed as planned for technical, scientific or commercial reasons;
availability and timing of results from preclinical studies and clinical trials; uncertainty about regulatory approval to conduct clinical
trials or to market a products; uncertainties regarding intellection property protection; and those set forth in the Company’s filings
with the Securities and Exchange Commission, including its Annual Report on Form 10-K, filed on April 15, 2025 and the latest quarterly
filings, and the documents incorporated by reference therein. The risks described in the Company’s filings with the Securities and
Exchange Commission are not exhaustive.